Neos Therapeutics Inc

-0.02 (-2.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)38.81M
Current PEN/A
Forward PE N/A
2yr Forward PE 20
See more stats
Estimates Current Quarter
Revenue$14.55 Million
Adjusted EPS-$0.10
See more estimates
10-Day MA$0.83
50-Day MA$1.37
200-Day MA$1.49
See more pivots

Neos Therapeutics, Inc. Stock, NAS:NEOS

2940 N. HIGHWAY 360, SUITE 400, GRAND PRAIRIE, TX 75050
United States of America
Phone: 972.408.1360
Number of Employees: 215


Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.